Mark Izraelewicz is a leader in the firm’s pharmaceutical and biosimilar litigation practice, and advises clients regarding strategies for the Biologics Price Competition and Innovation Act (BPCIA) patent dance. Izraelewicz and his team won a $70 million verdict in 2017 on behalf of Amgen in Amgen v Hospira, the first patent-infringement jury trial about a biosimilar under the BPCIA. He has been selected as one of the World’s Leading Patent Practitioners by Intellectual Asset Management magazine. In 2018/2019, he was selected as an Illinois Super Lawyer list, featuring outstanding attorneys in the state.